Our
Team
The Clinical Proteomics Platform consists of a dynamic team ready to listen to your questions.
Each member of the laboratory brings his or her own talents and knowledge to make the PPC the best choice for all your projects.
Sylvain LEHMANN
Head of the laboratory of Biochemistry and Clinical Proteomics
Prof. Sylvain Lehmann M.D., Ph.D. is professor of Biochemistry at the Medical School of Montpellier. His clinical unit at the University Hospital Center (CHU) is in charge of the biological diagnosis of neurodegenerative disorders and he recently set up a reference Neurological biobank.
Christophe HIRTZ
Head of the Clinical Proteomics Platform of Montpellier
Full Professor in Clinical Proteomics and Biochemistry, Christophe Hirtz is specialized in clinical assays and R&D activities in the field of clinical proteomics since 1998 and neurodegenerative diseases since 2010. ORCID
Jérôme VIALARET
MASS SPECTROMETRY Specialist - engineer
Laura FICHTER
Mass spectrometry engineer
“Engineer in mass spectrometry and proteomics, I am in charge of the research project on the TAU protein in multiple neurodegenerative pathologies.”
Aurore ATTINA
MASS SPECTROMETRY ENGINEER - SMART PROJECT MANAGER
“Hello everyone, I’m a mass spectrometry engineer and I joined PPC as the SMART project manager. My role is the development and implementation of methods for the detection and quantification of RNA changes.”
Jana KINDERMANS
assistant engineer
“Hello! My name is Jana and I’m from Belgium. As an assistant engineer specialized in proteomics and mass spectrometry, I work on projects and with clients on the detection and quantification of proteins in biological samples.”
Sonia GARCIA LLORENS
MASS SPECTROMETRY ENGINEER
“Hello! My name is Sonia and I work in the field of epitranscriptomics, detecting and quantifying RNA modifications in different organisms using analytical techniques such as mass spectrometry.”
Alexandre DAVID
Project manager SMART
“My research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic and translational control. To achieve our goals, we have created the S.M.A.R.T. consortium that seeks at developing state-of-the-art tools & methods for studies on RNA epigenetic, in particular for clinical applications.”
Salomé COPPENS
ATER
As an ATER, I work in the PPC laboratory as well as at the University of Dentistry. My research topic is targeted mass spectrometry projects for the quantification of biomarkers and high-resolution mass spectrometry.
Nicolas PRADEILLES
IMMUNOASSAY SPECIALIST - TECHNICIAN
“I am responsible for immunoassays in the laboratory using the latest technologies, SiMoA, Ella and MSD. We are open to all types of collaboration or services, depending on your needs, to advise you, support you and help you make the most of your project. Do not hesitate to contact us!”
Laurent TIERS
ImmunoAssay specialist - engineer
“Hello, I am in charge of immunoassays in the laboratory on the latest technologies, SIMOA and MSD.”
Constance DELABY
Project manager
University lecturer in Biochemistry and Molecular Biology, Constance Delaby is specialized in clinical trials and diagnostic activities of neurodegenerative diseases since 2011. ORCID
Margaux VIGNON
PhD student - Periodentist
“As a dentist specializing in periodontology, I divide my time between my hospital work at Montpellier University Hospital, my university work at Montpellier University of Odontology and my research work at the PPC. I’m currently in the second year of my PhD, working on salivary biomarkers of periodontitis.” ORCID
Florine LEIPP
PhD student
“Hello! As a student in a CIFRE thesis, funded by Shimadzu, my thesis project aims to develop a targeted LC-MS/MS method for the detection of the main blood biomarkers of dementia and Alzheimer’s disease in particular. This method would provide an innovative diagnostic tool and an alternative to invasive CSF assays.”
Auréa DAGORN
PhD student
Doryan MASMOUDI
PhD student
“As a doctoral student co-supervised by Prof. C. Panabières (LCCRH), I am studying the characterisation of the surfaceome of circulating metastasis-initiating tumour cells (CTCs). More specifically, the mechanisms by which CTCs evade the immune system and new therapeutic targets in immuno-oncology.”
Clinical Proteomics Platform
Institute for Regenerative Medicine & Biotherapy (IRMB)
Hôpital Saint Eloi
80 rue Augustin Fliche
34295 MONTPELLIER – Cedex 5
FRANCE